• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    21 Stocks Moving In Tuesday's Pre-Market Session

    11/23/21 6:50:41 AM ET
    $ADMP
    $AESE
    $BHTG
    $BORR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Cable & Other Pay Television Services
    Telecommunications
    Get the next $ADMP alert in real time by email

    Gainers

    • Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) rose 201% to $4.00 in pre-market trading. The company filed proxy statement for annual meeting after the market close on Monday.
    • iSpecimen Inc. (NASDAQ:ISPC) rose 103.8% to $18.10 in pre-market trading. iSpecimen shares jumped more than 80% on Monday after the company announced it has been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments.
    • Qualigen Therapeutics, Inc. (NASDAQ:QLGN) rose 93.6% to $2.42 in pre-market trading as traders circulated a Zack's Small Cap research note showing a $9 price target on the stock.
    • Bit Brother Limited (NASDAQ:BTB) rose 43.5% to $1.23 in pre-market trading after dropping over 12% on Monday.
    • Allied Esports Entertainment Inc. (NASDAQ:AESE) shares rose 15.2% to $2.20 in pre-market trading after the company reported a narrower quarterly loss. The company also highlighted that 'the Company is continuing to identify opportunities to invest the cash on its balance sheet...to acquire or merge with an existing business.'
    • Quantum-Si incorporated. (NASDAQ:QSI) rose 11.4% to $7.59 in pre-market trading after dropping 10% on Monday. Quantum-Si recently posted a Q3 loss of $0.13 per share.
    • RLX Technology Inc. (NYSE:RLX) rose 11.4% to $5.48 in pre-market trading after climbing 9% on Monday.
    • Iterum Therapeutics plc (NASDAQ:ITRM) rose 10.6% to $0.5090 in pre-market trading after declining 7% on Monday. Iterum Therapeutics recently posted Q3 EPS of $0.02.
    • Longeveron Inc. (NASDAQ:LGVN) rose 9.5% to $30.87 in pre-market trading on continued upward momentum after the company last week announced the FDA granted Rare Pediatric Disease designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome.
    • Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares rose 9.5% to $0.5095 in pre-market trading. Tonix Pharmaceuticals reported publication of paper on antiviral SARS-CoV-2 inhibitor, TNX-3500, in JCI Insight.
    • Soligenix, Inc. (NASDAQ:SNGX) rose 7.2% to $0.89 in pre-market trading. Soligenix recently posted a Q3 loss of $0.09 per share.


    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    Check out these big penny stock gainers and losers

    Losers

    • Reliance Global Group, Inc. (NASDAQ:RELI) shares fell 17.5% to $1.74 in pre-market trading. Reliance Global Group promoted Jonathan Fortman to Vice President of Acquisitions.
    • BioHiTech Global, Inc. (NASDAQ:BHTG) fell 15.3% to $0.80 in pre-market trading after declining 8% on Monday. BioHiTech Global, last week, said Q3 EPS and sales results were higher year over year.
    • Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) fell 13.8% to $0.7590 in pre-market trading. Adamis Pharmaceuticals said sales for the nine months ended Sept. 30, 2021 came in at $3.4 million.
    • Urban Outfitters, Inc. (NASDAQ:URBN) fell 13.3% to $32.32 in pre-market trading. Urban Outfitters posted upbeat earnings and sales results for the third quarter. Its same-store sales climbed 14.6% year-over-year during the quarter.
    • PainReform Ltd. (NASDAQ:PRFX) fell 12.5% to $2.01 in pre-market trading. PainReform recently posted a net loss of $5.5 million during the nine months ended Sept. 30, 2021.
    • iPower Inc. (NASDAQ:IPW) shares fell 9% to $2.74 in pre-market trading after dropping over 9% on Monday. iPower recently entered into $25 million credit facility with JPMorgan Chase.
    • Zoom Video Communications, Inc. (NASDAQ:ZM) fell 8.7% to $221.19 in pre-market trading. Zoom Video reported better-than-expected results for its third quarter on Monday. The company reported its customers that contribute more than $100,000 in the trailing 12 months totaled 2,507, up 94% year-over-year.
    • Progenity, Inc. (NASDAQ:PROG) shares fell 8.3% to $4.08 in pre-market trading following a 9% decline in the previous session.
    • Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares fell 7.2% to $17.58 in pre-market trading after declining 28% on Monday. Oramed's Oravax Medical Unit recently reported a joint venture with Genomma Lab to develop, commercialize oral COVID-19 vaccine in Mexico.
    • Borr Drilling Limited (NYSE:BORR) shares fell 7.2% to $1.03 in pre-market trading. Borr Drilling, earlier in November, reported better-than-expected Q3 EPS results.
    Get the next $ADMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMP
    $AESE
    $BHTG
    $BORR

    CompanyDatePrice TargetRatingAnalyst
    Zoom Communications Inc.
    $ZM
    2/5/2026$115.00Peer Perform → Outperform
    Wolfe Research
    Zoom Communications Inc.
    $ZM
    1/12/2026$106.00Neutral → Buy
    Citigroup
    Zoom Communications Inc.
    $ZM
    12/17/2025$105.00Buy
    BTIG Research
    Urban Outfitters Inc.
    $URBN
    12/17/2025$98.00Market Perform → Outperform
    Telsey Advisory Group
    Urban Outfitters Inc.
    $URBN
    12/10/2025Neutral
    Guggenheim
    Urban Outfitters Inc.
    $URBN
    12/9/2025$83.00Neutral
    Goldman
    Urban Outfitters Inc.
    $URBN
    11/26/2025$80.00 → $85.00Market Perform
    Telsey Advisory Group
    Zoom Communications Inc.
    $ZM
    10/21/2025$85.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ADMP
    $AESE
    $BHTG
    $BORR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Keyes Jeffry R.

    4 - Quantum-Si Inc (0001816431) (Issuer)

    4/22/26 5:09:09 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Hawkins Jeffrey Alan

    4 - Quantum-Si Inc (0001816431) (Issuer)

    4/22/26 5:02:10 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Bawa Aparna

    4 - Zoom Communications, Inc. (0001585521) (Issuer)

    4/21/26 4:54:01 PM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    $ADMP
    $AESE
    $BHTG
    $BORR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zoom Communications upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Zoom Communications from Peer Perform to Outperform and set a new price target of $115.00

    2/5/26 6:52:31 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    Zoom Communications upgraded by Citigroup with a new price target

    Citigroup upgraded Zoom Communications from Neutral to Buy and set a new price target of $106.00

    1/12/26 7:53:13 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    BTIG Research resumed coverage on Zoom Communications with a new price target

    BTIG Research resumed coverage of Zoom Communications with a rating of Buy and set a new price target of $105.00

    12/17/25 9:30:41 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    $ADMP
    $AESE
    $BHTG
    $BORR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

    10/18/21 11:55:40 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

    6/30/21 5:11:48 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AESE
    $BHTG
    $BORR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dowdy Paula bought $104,450 worth of shares (109,890 units at $0.95), increasing direct ownership by 69% to 269,107 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:13 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Director Kummeth Charles R. bought $459,800 worth of shares (500,000 units at $0.92), increasing direct ownership by 141% to 855,000 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:59 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Director Dunne Michael W. bought $2,191 worth of Ordinary Shares (6,000 units at $0.37), increasing direct ownership by 3% to 241,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    11/20/25 7:00:04 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AESE
    $BHTG
    $BORR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Buy Research Opinion on Zoom Communications (NASDAQ: ZM)

    NOTE TO EDITORS: The Following Is an Investment Opinion Issued by Spruce Point Capital Management Provides Evidence the Bear Thesis on Zoom Shares Does Not Hold Up to Scrutiny Believes Zoom's Transformation Into a Comprehensive, Value-Added, AI-First Platform Poised to Drive Deeper Enterprise Penetration is Underappreciated Demonstrates Zoom is Trading at a Massive Discount to Its Intrinsic Value, Particularly Considering Its Share Ownership in AI Leader Anthropic Identifies A Range of Cost Structure, Organizational Effectiveness, Capital Allocation Practices, and Corporate Governance Concerns For Zoom to Address Announces It Has Sent the Zoom Board of Directors a Letter Containin

    4/24/26 8:30:00 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Borr Drilling Limited - Invitation to Webcast and Conference Call for Q1 2026 Results

    HAMILTON, Bermuda, April 20, 2026 /PRNewswire/ -- Borr Drilling Limited (NYSE:BORR) and (Euronext Growth Oslo: BORR) (the "Company") plans to release its financial results for the first quarter of 2026 after the close of trading on NYSE on Wednesday, May 20, 2026. A conference call and webcast are scheduled for 09:00 New York time (15:00 CEST) on Thursday, May 21, 2026.The earnings report, webcast and accompanying presentation will be available on the Investor Relations section of the Company's website, www.borrdrilling.com.In order to listen to the live presentation, participants may do one of the following:a)    WebcastTo access the webcast, please go to the following link:https://edge.med

    4/20/26 3:29:00 AM ET
    $BORR
    Oil & Gas Production
    Energy

    $ADMP
    $AESE
    $BHTG
    $BORR
    SEC Filings

    View All

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    4/23/26 7:11:37 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Quantum-Si Incorporated

    144 - Quantum-Si Inc (0001816431) (Subject)

    4/22/26 4:50:07 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    SEC Form 144 filed by Quantum-Si Incorporated

    144 - Quantum-Si Inc (0001816431) (Subject)

    4/22/26 4:48:00 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    $ADMP
    $AESE
    $BHTG
    $BORR
    Financials

    Live finance-specific insights

    View All

    Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Buy Research Opinion on Zoom Communications (NASDAQ: ZM)

    NOTE TO EDITORS: The Following Is an Investment Opinion Issued by Spruce Point Capital Management Provides Evidence the Bear Thesis on Zoom Shares Does Not Hold Up to Scrutiny Believes Zoom's Transformation Into a Comprehensive, Value-Added, AI-First Platform Poised to Drive Deeper Enterprise Penetration is Underappreciated Demonstrates Zoom is Trading at a Massive Discount to Its Intrinsic Value, Particularly Considering Its Share Ownership in AI Leader Anthropic Identifies A Range of Cost Structure, Organizational Effectiveness, Capital Allocation Practices, and Corporate Governance Concerns For Zoom to Address Announces It Has Sent the Zoom Board of Directors a Letter Containin

    4/24/26 8:30:00 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Borr Drilling Limited - Invitation to Webcast and Conference Call for Q1 2026 Results

    HAMILTON, Bermuda, April 20, 2026 /PRNewswire/ -- Borr Drilling Limited (NYSE:BORR) and (Euronext Growth Oslo: BORR) (the "Company") plans to release its financial results for the first quarter of 2026 after the close of trading on NYSE on Wednesday, May 20, 2026. A conference call and webcast are scheduled for 09:00 New York time (15:00 CEST) on Thursday, May 21, 2026.The earnings report, webcast and accompanying presentation will be available on the Investor Relations section of the Company's website, www.borrdrilling.com.In order to listen to the live presentation, participants may do one of the following:a)    WebcastTo access the webcast, please go to the following link:https://edge.med

    4/20/26 3:29:00 AM ET
    $BORR
    Oil & Gas Production
    Energy

    $ADMP
    $AESE
    $BHTG
    $BORR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Iterum Therapeutics plc

    SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)

    11/14/24 7:54:21 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/14/24 5:17:37 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:42:22 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AESE
    $BHTG
    $BORR
    Leadership Updates

    Live Leadership Updates

    View All

    Zoom appoints Russell Dicker as chief product officer to advance AI-first product strategy and workflow automation

    SAN JOSE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Zoom Communications, Inc. (NASDAQ:ZM) today announced the appointment of Russell Dicker as the company's chief product officer (CPO), leading product strategy for Zoom's system of action, turning conversations into completed work through AI. Russell brings more than 25 years of experience building and scaling global product platforms, including leading Microsoft Teams' product and data science teams, with a focus on applying AI to simplify workflows and improve how work gets done. Russell joins Zoom at a pivotal time, as companies seek AI tools to automate processes and tasks, freeing up time for higher-level work. Zoom is uniquely posi

    4/15/26 9:05:00 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

    CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated commercial-stage biotechnology company today announced the appointment of Irina Ishak as General Counsel, effective December 8, 2025. Ms. Ishak will lead Tonix's legal, corporate governance, and compliance functions. "Irina is a highly accomplished corporate and commercial attorney whose experience spans public and private life sciences companies, as well as advising life sciences investors," said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. "Her deep background in complex transactions, public company matters, and governa

    12/9/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care